The Indian Journal of Pediatrics

, Volume 83, Issue 3, pp 214–219 | Cite as

Langerhans Cell Histiocytosis (LCH) in Egyptian Children: Does Reactivation Affect the Outcome?

  • Mohamed Sedky Mahmoud SedkyEmail author
  • Hany Abdel Rahman
  • Emad Moussa
  • Hala Taha
  • Tarek Raafat
  • Omayma Hassanein
Original Article



To report a single centre outcome of management of Langerhans cell histiocytosis (LCH), a clonal disease with involvement of various body systems.


Retrospective analysis of 80 pediatric LCH patients at Children Cancer Hospital-Egypt between July 2007 and December 2011 was performed. Patients were stratified and treated according to LCH III protocol. The median follow up period was 42 mo (range: 1.18 to 71 mo).


At wk 6 and 12, ‘better’ response was obtained in 61 (76 %) and 74 (93 %) patients respectively. Afterwards, reactivation occurred in 25 patients (38 %), of them multiple episodes occurred in 5 patients (6.25 %), managed by repetition of 1st line treatment for once or more. The 5 y overall survival (OS) and event free survival (EFS) was 96.3 and 55 % respectively. At last follow up, better status was reached in 70 patients, 3 in each ‘intermediate’ and ‘worse’ status. Three high risk patients died and one patient was lost to follow up.


In a single Egyptian pediatric LCH experience, the response to treatment is satisfactory and survival remains the rule except in high risk organs disease that still needs a new molecule for salvage. However in multiple reactivations, patients do well with repetition of the 1st line of treatment with or without methotrexate.


LCH Risk organs Response Reactivation Survival 



The authors acknowledges Dr. Jean Donadieu, Pediatric Hemato Oncologist, Service d'Hémato-Oncologie Pédiatrique, Hopital Trousseau, Paris, France, for his effort in guiding his team during the preparation of this manuscript. His vast experience in Histiocytosis was the light that they followed for reaching the end of this work.

Conflict of Interest


Source of Funding



  1. 1.
    Komp DM, Herson J, Starling KA, Vietti TJ, Hvizdala E. A staging system for histiocytosis X: a Southwest Oncology Group Study. Cancer. 1981;47:798–800.CrossRefPubMedGoogle Scholar
  2. 2.
    The French Langerhans cell Histiocytosis Group. A multicentric retrospective survey of Langerhans’ cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child. 1996;75:17–24.CrossRefGoogle Scholar
  3. 3.
    Titgemeyer C, Grois N, Minkov M, Flucher-Wolfram B, Gatterer-Menz I, Gadner H. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 2001;37:108–14.CrossRefPubMedGoogle Scholar
  4. 4.
    Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:327–38.CrossRefPubMedGoogle Scholar
  5. 5.
    Ladisch S, Jaffe E. Histiocytoses. In: Pizzo O, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott Wiliams & Wilkins; 2006. p. 768–85.Google Scholar
  6. 6.
    Lahey E. Histiocytosis X : an analysis of prognostic factors. J Pediatr. 1975;87:184–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Ceci A, de Terlizzi M, Colella R, et al. Etoposide in recurrent childhood Langerhans’ cell histiocytosis: an Italian Cooperative Study. Cancer. 1988;62:2528–31.CrossRefPubMedGoogle Scholar
  8. 8.
    Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S; For the DAL HX 83 Study Group. Treatment strategy for disseminated Langerhans cell histiocytosis. Med Ped Oncol. 1994;23:72–80.CrossRefGoogle Scholar
  9. 9.
    Gadner H, Grois N, Potschger U, et al; Histiocyte Society. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111:2556–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Stine KC, Staylors RL, Wiliams LL, Becton DL. Chlorodeoxyadenosisne (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol. 1997;29:288–92.CrossRefPubMedGoogle Scholar
  11. 11.
    Writing Group of the Histiocyte Society. Histiocytosis syndromes in children. Lancet. 1987;1:208–9.Google Scholar
  12. 12.
    Gadner H, Minkov M, Grois N, et al; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121:5006–14.CrossRefPubMedGoogle Scholar
  13. 13.
    Lahey ME. Prognostic factors in histiocytosis X. Am J Pediatr Hematol Oncol. 1981;3:57–60.PubMedGoogle Scholar
  14. 14.
    Trottestam H, Horne A, Aricò M, et al; Histiocyte Society. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118:4577–84.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Kim BE, Koh KN, Suh JK, et al. Clinical features and treatment outcomes of Langerhans cell histiocytosis: a nationwide survey from Korea histiocytosis working party. J Pediatr Hematol Oncol. 2014;36:125–33.CrossRefPubMedGoogle Scholar
  16. 16.
    Lee JW, Shin HY, Kang HJ, et al. Clinical characteristics and treatment outcome of Langerhans cell histiocytosis: 22 years’ experience of 154 patients at a single center. Pediatr Hematol Oncol. 2014;31:293–302.CrossRefPubMedGoogle Scholar
  17. 17.
    Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004. Pediatr Blood Cancer. 2008;51:71–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Müller J, Garami M, Hauser P, et al; Hungarian Pediatric Oncology Network. Hungarian experience with Langerhans cell histiocytosis in childhood. Pediatr Hematol Oncol. 2006;23:135–42.CrossRefPubMedGoogle Scholar
  19. 19.
    Donadieu J, Chalard F, Jeziorski E. Medical management of langerhans cell histiocytosis from diagnosis to treatment. Expert Opin Pharmacother. 2012;13:1309–22.CrossRefPubMedGoogle Scholar
  20. 20.
    Ladisch S, Gadner H, Aricò M, et al. LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society. Med Pediatr Oncol. 1994;23:107–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs. 2011;13:75–86.CrossRefPubMedGoogle Scholar
  22. 22.
    Gadner H, Heitger A, Ritter J, et al. Langerhans cell histiocytosis in childhood–results of the DAL-HX 83 study]. Klin Padiatr. 1987;199:173–82.CrossRefPubMedGoogle Scholar
  23. 23.
    Minkov M, Grois N, Heitger A, et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr. 2000;212:139–44.CrossRefPubMedGoogle Scholar
  24. 24.
    Minkov M, Steiner M, Pötschger U, et al; International LCH Study Group. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J Pediatr. 2008;153:700–5, 705.e1-2.Google Scholar
  25. 25.
    Pollono D, Rey G, Latella A, Rosso D, Chantada G, Braier J. Reactivation and risk of sequelae in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;48:696–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004;42:438–44.CrossRefPubMedGoogle Scholar
  27. 27.
    Minkov M, Grois N, Heitger A, et al. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol. 2002;39:581–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Haupt R, Minkov M, Astigarraga I, et al. Langerhans cell histiocytosis: guidelines for diagnosis, clinical workup, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60:175–84.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Uppal P, Bothra M, Seth R, Iyer V, Kabra SK. Clinical profile of Langerhans cell histiocytosis at a tertiary centre: a prospective study. Indian J Pediatr. 2012;79:1463–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Dua V, Yadav SP, Sachdeva A. Treatment of relapsed/refractory langerhans cell histiocytosis: a single centre experience. Indian J Pediatr. 2014;81:315–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Morimoto A, Ikushima S, Kinugawa N, et al; Japan Langerhans Cell Histiocytosis Study Group. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006;107:613–9.CrossRefPubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2015

Authors and Affiliations

  • Mohamed Sedky Mahmoud Sedky
    • 1
    • 2
    Email author
  • Hany Abdel Rahman
    • 3
    • 4
  • Emad Moussa
    • 4
    • 5
  • Hala Taha
    • 6
    • 7
  • Tarek Raafat
    • 8
  • Omayma Hassanein
    • 9
  1. 1.Department of PediatricsNational Research CentreCairoEgypt
  2. 2.Department of Pediatric OncologyChildren Cancer HospitalCairoEgypt
  3. 3.Department of Pediatric Oncology, National Cancer InstituteCairo UniversityCairoEgypt
  4. 4.Children Cancer HospitalCairoEgypt
  5. 5.Department of Clinical OncologyMenoufeya UniversityCairoEgypt
  6. 6.Department of PathologyChildren Cancer HospitalCairoEgypt
  7. 7.National Cancer InstituteCairo UniversityCairoEgypt
  8. 8.Department of RadiologyNational Cancer Institute, Cairo University, Children Cancer HospitalCairoEgypt
  9. 9.Department of Clinical ResearchChildren Cancer HospitalCairoEgypt

Personalised recommendations